JPRN-jRCT2080225138已完成未知
AN OPEN-LABEL, MULTI-CENTER, EXPANDED ACCESS STUDY OF TRASTUZUMAB DERUXTECAN IN JAPANESE SUBJECTS WITH HER2-POSITIVE ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 64
研究概览
简要总结
This study was aimed to provide trastuzumab deruxtecan to patients with This study was aimed to provide trastuzumab deruxtecan to patients with HER2-positive advanced gastric adenocarcinoma or GEJ adenocarcinoma. The collected adverse events and their severity were generally consistent with previous results in other clinical studies in trastuzumab deruxtecan, and no new safety issues were identified.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Has a pathologically documented locally advanced or metastatic adenocarcinoma of gastric or gastroesophageal junction with HER2 positive
- •2.Has a medical history of at least 2 prior regimens which had to include fluoropyrimidine agent, platinum agent, and trastuzumab
- •3.Has an ECOG PS of 0 to 1
排除标准
- •1.Has a medical history of clinically significant lung disease
- •2.Has active central nervous system metastases
- •3.Has had non-gastric or gastroesophageal junction primary malignancies within 3 years
研究者
相似试验
No Longer Available
不适用
A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast CancerMetastatic Breast CancerNCT01120561Genentech, Inc.
招募中
1 期
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLCLocally Advanced or Metastatic Non-Small Cell Lung CancerNCT04686305AstraZeneca304
招募中
4 期
Dabrafenib and/or Trametinib Rollover StudyNon Small Cell Lung CancerSolid TumorRare CancersHigh Grade GliomaMelanomaNCT03340506Novartis Pharmaceuticals100
进行中（未招募）
3 期
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast CancerAdvanced or Metastatic Breast CancerNCT04494425AstraZeneca866
Available
不适用
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene AutoleucelAcute Lymphoblastic LeukemiaMantle Cell LymphomaNCT05776134Kite, A Gilead Company